KRAS and pancreatic neoplasm: The combinatorial effect of AZD4547/BI2536 in KRAS‐mutant lung and pancreatic cancer cells was confirmed by clonogenic and apoptotic assay, where the drug combination markedly enhanced growth inhibition and led to a significantly greater percentage of apoptotic cells than single agents (Fig 2C and D), which did not occur in SW620, DLD‐1, or EBC‐1 cells (Appendix Fig S2D).